PortalPublikationenThe optimal use of chlormethine gel for mycosis fungoides: A...

The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)

Standard

The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region). / Assaf, Chalid; Booken, Nina; Dippel, Edgar; Guenova, Emmanuella; Jonak, Constanze; Klemke, Claus-Detlev; Nicolay, Jan P; Schlaak, Max; Wobser, Marion; Trautinger, Franz.

in: J DTSCH DERMATOL GES, Jahrgang 20, Nr. 5, 05.2022, S. 579-586.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Assaf, C, Booken, N, Dippel, E, Guenova, E, Jonak, C, Klemke, C-D, Nicolay, JP, Schlaak, M, Wobser, M & Trautinger, F 2022, 'The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)', J DTSCH DERMATOL GES, Jg. 20, Nr. 5, S. 579-586. https://doi.org/10.1111/ddg.14688

APA

Assaf, C., Booken, N., Dippel, E., Guenova, E., Jonak, C., Klemke, C-D., Nicolay, J. P., Schlaak, M., Wobser, M., & Trautinger, F. (2022). The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region). J DTSCH DERMATOL GES, 20(5), 579-586. https://doi.org/10.1111/ddg.14688

Vancouver

Assaf C, Booken N, Dippel E, Guenova E, Jonak C, Klemke C-D et al. The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region). J DTSCH DERMATOL GES. 2022 Mai;20(5):579-586. https://doi.org/10.1111/ddg.14688

Bibtex

@article{9b4d709ebfb74d779175f58bd8d823d0,
title = "The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)",
abstract = "BACKGROUND: In Europe chlormethine gel is licensed for the management of patients with mycosis fungoides of all stages. However, the optimal regimen regarding frequency and dosing as well as combination and maintenance therapy is not well established.METHODS: Ten experts experienced in research and management of cutaneous T-cell lymphomas from Germany, Austria, and Switzerland (DACH region) were asked in written form to report on indication for chlormethine gel, frequency of use, monitoring, concomitant therapies, adverse effects, combination therapies in later stages of the disease, maintenance therapy, and adherence to this therapy for mycosis fungoides. The structured answers were discussed in a consensus conference and recommendations were developed.RESULTS: Essential for therapy with chlormethine gel is an individualized and symptom-oriented management. Because of the lack of systemic resorption of topically administered chlormethine gel, systemic adverse events are unlikely. An allergic or irritative-toxic contact dermatitis is common but manageable with adaptation of the regimen, interruption of administration, and symptom-specific supportive measurements. A step-up initial approach with application of chlormethine gel every other day is associated with a better tolerability, especially if it is alternated with topical corticosteroids.CONCLUSIONS: The use of chlormethine gel in the management of mycosis fungoides is often limited by a concomitant contact dermatitis. An adequate therapeutic regimen and the management of adverse effects can preclude an unnecessary withdrawal of therapy so that more patients can benefit from this treatment option.",
keywords = "Austria, Cyclohexylamines, Dermatitis, Contact, Humans, Mechlorethamine, Mycosis Fungoides/pathology, Skin Neoplasms/pathology, Switzerland",
author = "Chalid Assaf and Nina Booken and Edgar Dippel and Emmanuella Guenova and Constanze Jonak and Claus-Detlev Klemke and Nicolay, {Jan P} and Max Schlaak and Marion Wobser and Franz Trautinger",
note = "{\textcopyright} 2022 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.",
year = "2022",
month = may,
doi = "10.1111/ddg.14688",
language = "English",
volume = "20",
pages = "579--586",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)

AU - Assaf, Chalid

AU - Booken, Nina

AU - Dippel, Edgar

AU - Guenova, Emmanuella

AU - Jonak, Constanze

AU - Klemke, Claus-Detlev

AU - Nicolay, Jan P

AU - Schlaak, Max

AU - Wobser, Marion

AU - Trautinger, Franz

N1 - © 2022 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.

PY - 2022/5

Y1 - 2022/5

N2 - BACKGROUND: In Europe chlormethine gel is licensed for the management of patients with mycosis fungoides of all stages. However, the optimal regimen regarding frequency and dosing as well as combination and maintenance therapy is not well established.METHODS: Ten experts experienced in research and management of cutaneous T-cell lymphomas from Germany, Austria, and Switzerland (DACH region) were asked in written form to report on indication for chlormethine gel, frequency of use, monitoring, concomitant therapies, adverse effects, combination therapies in later stages of the disease, maintenance therapy, and adherence to this therapy for mycosis fungoides. The structured answers were discussed in a consensus conference and recommendations were developed.RESULTS: Essential for therapy with chlormethine gel is an individualized and symptom-oriented management. Because of the lack of systemic resorption of topically administered chlormethine gel, systemic adverse events are unlikely. An allergic or irritative-toxic contact dermatitis is common but manageable with adaptation of the regimen, interruption of administration, and symptom-specific supportive measurements. A step-up initial approach with application of chlormethine gel every other day is associated with a better tolerability, especially if it is alternated with topical corticosteroids.CONCLUSIONS: The use of chlormethine gel in the management of mycosis fungoides is often limited by a concomitant contact dermatitis. An adequate therapeutic regimen and the management of adverse effects can preclude an unnecessary withdrawal of therapy so that more patients can benefit from this treatment option.

AB - BACKGROUND: In Europe chlormethine gel is licensed for the management of patients with mycosis fungoides of all stages. However, the optimal regimen regarding frequency and dosing as well as combination and maintenance therapy is not well established.METHODS: Ten experts experienced in research and management of cutaneous T-cell lymphomas from Germany, Austria, and Switzerland (DACH region) were asked in written form to report on indication for chlormethine gel, frequency of use, monitoring, concomitant therapies, adverse effects, combination therapies in later stages of the disease, maintenance therapy, and adherence to this therapy for mycosis fungoides. The structured answers were discussed in a consensus conference and recommendations were developed.RESULTS: Essential for therapy with chlormethine gel is an individualized and symptom-oriented management. Because of the lack of systemic resorption of topically administered chlormethine gel, systemic adverse events are unlikely. An allergic or irritative-toxic contact dermatitis is common but manageable with adaptation of the regimen, interruption of administration, and symptom-specific supportive measurements. A step-up initial approach with application of chlormethine gel every other day is associated with a better tolerability, especially if it is alternated with topical corticosteroids.CONCLUSIONS: The use of chlormethine gel in the management of mycosis fungoides is often limited by a concomitant contact dermatitis. An adequate therapeutic regimen and the management of adverse effects can preclude an unnecessary withdrawal of therapy so that more patients can benefit from this treatment option.

KW - Austria

KW - Cyclohexylamines

KW - Dermatitis, Contact

KW - Humans

KW - Mechlorethamine

KW - Mycosis Fungoides/pathology

KW - Skin Neoplasms/pathology

KW - Switzerland

U2 - 10.1111/ddg.14688

DO - 10.1111/ddg.14688

M3 - SCORING: Review article

C2 - 35429108

VL - 20

SP - 579

EP - 586

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 5

ER -